Cargando…

Long-term Survival (>13 Years) in a Child With Recurrent Diffuse Pontine Gliosarcoma: A Case Report

Pediatric gliosarcoma (GS) is a rare variant of glioblastoma multiforme. The authors describe the case of an unusual pontine location of GS in a 9-year-old boy who was initially diagnosed with low-grade astrocytoma (LGA) that was successfully controlled for 4 years. Subsequently, his brain tumor tra...

Descripción completa

Detalles Bibliográficos
Autores principales: Burzynski, Stanislaw R., Janicki, Tomasz J., Burzynski, Gregory S., Marszalek, Ania
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Lippincott Williams & Wilkins 2014
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4217198/
https://www.ncbi.nlm.nih.gov/pubmed/24136026
http://dx.doi.org/10.1097/MPH.0000000000000020
_version_ 1782342363922825216
author Burzynski, Stanislaw R.
Janicki, Tomasz J.
Burzynski, Gregory S.
Marszalek, Ania
author_facet Burzynski, Stanislaw R.
Janicki, Tomasz J.
Burzynski, Gregory S.
Marszalek, Ania
author_sort Burzynski, Stanislaw R.
collection PubMed
description Pediatric gliosarcoma (GS) is a rare variant of glioblastoma multiforme. The authors describe the case of an unusual pontine location of GS in a 9-year-old boy who was initially diagnosed with low-grade astrocytoma (LGA) that was successfully controlled for 4 years. Subsequently, his brain tumor transformed into a GS. Prior treatment of his LGA included subtotal tumor resection 3 times, standard radiation therapy, and Gamma Knife procedure twice. His LGA was also treated with a standard chemotherapy regimen of carboplatin and vincristine, and his GS with subtotal resection, high-dose cyclophosphamide, and thiotepa with stem cell rescue and temozolomide. Unfortunately, he developed disseminated disease with multiple lesions and leptomeningeal involvement including a tumor occupying 80% of the pons. Upon presentation at our clinic, he had rapidly progressing disease. He received treatment with antineoplastons (ANP) A10 and AS2-1 for 6 years and 10 months under special exception to our phase II protocol BT-22. During his treatment with ANP his tumor stabilized, then decreased, and, ultimately, did not show any metabolic activity. The patient’s response was evaluated by magnetic resonance imaging and positron emission tomography scans. His pathology diagnosis was confirmed by external neuropathologists, and his response to the treatment was determined by central radiology review. He experienced the following treatment-related, reversible toxicities with ANP: fatigue, xerostomia and urinary frequency (grade 1), diarrhea, incontinence and urine color change (grade 2), and grade 4 hypernatremia. His condition continued to improve after treatment with ANP and, currently, he complains only of residual neurological deficit from his previous surgery. He achieved a complete response, and his overall and progression-free survival is in excess of 13 years. This report indicates that it is possible to obtain long-term survival of a child with a highly aggressive recurrent GS with diffuse pontine involvement with a currently available investigational treatment.
format Online
Article
Text
id pubmed-4217198
institution National Center for Biotechnology Information
language English
publishDate 2014
publisher Lippincott Williams & Wilkins
record_format MEDLINE/PubMed
spelling pubmed-42171982014-11-03 Long-term Survival (>13 Years) in a Child With Recurrent Diffuse Pontine Gliosarcoma: A Case Report Burzynski, Stanislaw R. Janicki, Tomasz J. Burzynski, Gregory S. Marszalek, Ania J Pediatr Hematol Oncol Online Articles: Clinical and Laboratory Observations Pediatric gliosarcoma (GS) is a rare variant of glioblastoma multiforme. The authors describe the case of an unusual pontine location of GS in a 9-year-old boy who was initially diagnosed with low-grade astrocytoma (LGA) that was successfully controlled for 4 years. Subsequently, his brain tumor transformed into a GS. Prior treatment of his LGA included subtotal tumor resection 3 times, standard radiation therapy, and Gamma Knife procedure twice. His LGA was also treated with a standard chemotherapy regimen of carboplatin and vincristine, and his GS with subtotal resection, high-dose cyclophosphamide, and thiotepa with stem cell rescue and temozolomide. Unfortunately, he developed disseminated disease with multiple lesions and leptomeningeal involvement including a tumor occupying 80% of the pons. Upon presentation at our clinic, he had rapidly progressing disease. He received treatment with antineoplastons (ANP) A10 and AS2-1 for 6 years and 10 months under special exception to our phase II protocol BT-22. During his treatment with ANP his tumor stabilized, then decreased, and, ultimately, did not show any metabolic activity. The patient’s response was evaluated by magnetic resonance imaging and positron emission tomography scans. His pathology diagnosis was confirmed by external neuropathologists, and his response to the treatment was determined by central radiology review. He experienced the following treatment-related, reversible toxicities with ANP: fatigue, xerostomia and urinary frequency (grade 1), diarrhea, incontinence and urine color change (grade 2), and grade 4 hypernatremia. His condition continued to improve after treatment with ANP and, currently, he complains only of residual neurological deficit from his previous surgery. He achieved a complete response, and his overall and progression-free survival is in excess of 13 years. This report indicates that it is possible to obtain long-term survival of a child with a highly aggressive recurrent GS with diffuse pontine involvement with a currently available investigational treatment. Lippincott Williams & Wilkins 2014-10 2014-09-24 /pmc/articles/PMC4217198/ /pubmed/24136026 http://dx.doi.org/10.1097/MPH.0000000000000020 Text en Copyright © 2013 by Lippincott Williams & Wilkins This is an open-access article distributed under the terms of the Creative Commons Attribution-NonCommercial-NoDerivitives 3.0 License, where it is permissible to download and share the work provided it is properly cited. The work cannot be changed in any way or used commercially. http://creativecommons.org/licenses/by-nc-nd/3.0.
spellingShingle Online Articles: Clinical and Laboratory Observations
Burzynski, Stanislaw R.
Janicki, Tomasz J.
Burzynski, Gregory S.
Marszalek, Ania
Long-term Survival (>13 Years) in a Child With Recurrent Diffuse Pontine Gliosarcoma: A Case Report
title Long-term Survival (>13 Years) in a Child With Recurrent Diffuse Pontine Gliosarcoma: A Case Report
title_full Long-term Survival (>13 Years) in a Child With Recurrent Diffuse Pontine Gliosarcoma: A Case Report
title_fullStr Long-term Survival (>13 Years) in a Child With Recurrent Diffuse Pontine Gliosarcoma: A Case Report
title_full_unstemmed Long-term Survival (>13 Years) in a Child With Recurrent Diffuse Pontine Gliosarcoma: A Case Report
title_short Long-term Survival (>13 Years) in a Child With Recurrent Diffuse Pontine Gliosarcoma: A Case Report
title_sort long-term survival (>13 years) in a child with recurrent diffuse pontine gliosarcoma: a case report
topic Online Articles: Clinical and Laboratory Observations
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4217198/
https://www.ncbi.nlm.nih.gov/pubmed/24136026
http://dx.doi.org/10.1097/MPH.0000000000000020
work_keys_str_mv AT burzynskistanislawr longtermsurvival13yearsinachildwithrecurrentdiffusepontinegliosarcomaacasereport
AT janickitomaszj longtermsurvival13yearsinachildwithrecurrentdiffusepontinegliosarcomaacasereport
AT burzynskigregorys longtermsurvival13yearsinachildwithrecurrentdiffusepontinegliosarcomaacasereport
AT marszalekania longtermsurvival13yearsinachildwithrecurrentdiffusepontinegliosarcomaacasereport